Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Wall Street has experienced a broadly positive day, marked by a resilient rally that has added over $1 trillion in market value. This surge in investor confidence is primarily driven by a confluence of strong corporate earnings, sustained momentum in the technology sector, and a perceived easing of anxieties related
After a dip last week, Wall Street rebounded as earnings remained strong. Tech stocks surged, but Eli Lilly struggled. Trump imposed tariffs on India and nominated Stephen Miran for Fed seat.
Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company's growth strength.
Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.
Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lily 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide.
Wall Street ended Thursday on a shaky note as disappointing drug trial results, new trade tariffs, and cautious corporate guidance weighed on sentiment. While Apple (AAPL | +3.2%) basked in the glow of domestic investment optimism, heavyweights like Eli Lilly (LLY | -14.1%) and Airbnb (ABNB | -8.0%) dragged major indexes in opposite directions.
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98 billion to $100 billion from its market capitalization. The significant sell-off was triggered by the release of disappointing clinical trial data
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
fell 13.9% in the afternoon session after its oral weight-loss drug trial results disappointed investors, overshadowing an otherwise strong quarterly earnings report and guidance increase.
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 37.6% year on year to $15.56 billion. The company’s full-year revenue guidance of $61 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $6.31 per share was 12.9% above analysts’ consensus estimates.
Animal health company Elanco (NYSE:ELAN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.8% year on year to $1.24 billion. Guidance for next quarter’s revenue was better than expected at $1.1 billion at the midpoint, 0.9% above analysts’ estimates. Its non-GAAP profit of $0.26 per share was 29.5% above analysts’ consensus estimates.
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
